ED
ALXN

Exane Derivatives’s Alexion Pharmaceuticals ALXN Stock Holding History

Exane Derivatives’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,472
Closed -$230K – 980
2020
Q4 		$230K Buy
1,472
+306
+26% +$39.3K 0.07% 292
2020
Q3 		$133K Sell
1,166
-66
-5% -$7.12K 0.04% 252
2020
Q2 		$138K Sell
1,232
-4,928
-80% -$523K 0.04% 248
2020
Q1 		$553K Buy
6,160
+4,961
+414% +$487K 0.15% 113
2019
Q4 		$135K Sell
1,199
-1,003
-46% -$107K 0.03% 290
2019
Q3 		$216K Buy
2,202
+1,300
+144% +$147K 0.04% 245
2019
Q2 		$118K Buy
+902
New +$116K 0.02% 314
2019
Q1 		– Sell
-24
Closed -$2.34K – 720
2018
Q4 		$2.34K Hold
24
– – ﹤0.01% 518
2018
Q3 		$3.36K Sell
24
-980
-98% -$123K ﹤0.01% 472
2018
Q2 		$125K Sell
1,004
-151
-13% -$17.6K 0.02% 307
2018
Q1 		$127K Buy
1,155
+736
+176% +$88K 0.03% 273
2017
Q4 		$50.1K Buy
419
+137
+49% +$16.7K 0.01% 337
2017
Q3 		$39.6K Buy
+282
New +$38.3K 0.01% 324
2015
Q1 		– Sell
-254
Closed -$47K – 568
2014
Q4 		$47K Buy
+254
New +$47.1K 0.01% 326

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exane Derivatives's ALXN Position: Q1 2021 in Review

Exane Derivatives sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,472 shares — an estimated $230K sold.

Exane Derivatives first reported a position in ALXN in Q4 2014 and held it in 14 quarters. The position peaked at $553K in Q1 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Exane Derivatives reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,472 Alexion Pharmaceuticals shares in Q1 2021, an estimated $230K.
  • Exane Derivatives first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 14 quarters.
  • Exane Derivatives's Alexion Pharmaceuticals position peaked at $553K in Q1 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.